This is an observational study based on a population-based EHR database.
This observational study based on a population-based EHR database in Yinzhou district of Ningbo city in China is to estimate incidence rates of seizures (including febrile seizures), urticaria and angioedema, apnea, and fever among Chinese children after receiving Prevenar 13. In addition, a validation study including validation of International classification of diseases, tenth revision (ICD-10) codes or ICD-10 code based algorithm for identifying all safety outcomes of interest and a prospective cohort study in a sub-population of the main study will be conducted in order to offset the potential biased results from the main study because of potential misclassification of the safety outcomes of interest due to miscoding and/or undercoding of ICD-10 codes used to identify these safety outcomes in the EHR database.
Study Type
OBSERVATIONAL
Enrollment
21,240
School of Public Health at Fudan University
Shanghai, China
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Person Days) of All Seizures Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Apnea Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Fever Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Person Days) of All Seizures Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Apnea Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Fever Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Person Days) of All Seizures Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Apnea Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Fever Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Person Days) of All Seizures Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Apnea Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Fever Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 Days after all Doses
Incidence Rate (Per 1000 Person Days) of All Seizures Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 Days after all Doses
Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 Days after all Doses
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 Days after all Doses
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 Days after all Doses
Incidence Rate (Per 1000 Person Days) of Febrile Seizures Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 Days after all Doses
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after all Doses
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after all Doses
Incidence Rate (Per 1000 Person Days) of Urticaria and Angioedema Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after all Doses
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after all doses
Incidence Rate (Per 1000 Person Days) of Apnea Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after all doses
Incidence Rate (Per 1000 Person Days) of Apnea Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after all doses
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 3 days after all doses
Incidence Rate (Per 1000 Person Days) of Fever Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 4 to 7 days after all doses
Incidence Rate (Per 1000 Person Days) of Fever Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the observed time at risk, multiply by 1000.
Time frame: 0 to 7 days after all doses
Incidence Rate (IR) (Per 1000 Doses) of All Seizures Through 0 to 3 Days After Dose 1
IR was calculated as the number of all seizure events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Doses) of All Seizures Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Doses) of Apnea Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 3 Days After Dose 1
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 1
Incidence Rate (Per 1000 Doses) of Fever Through 4 to 7 Days After Dose 1
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 7 Days After Dose 1
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 1
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Doses) of All Seizures Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Doses) of Apnea Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 3 Days After Dose 2
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 2
Incidence Rate (Per 1000 Doses) of Fever Through 4 to 7 Days After Dose 2
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 7 Days After Dose 2
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 2
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Doses) of All Seizures Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Doses) of Apnea Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 3 Days After Dose 3
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 3
Incidence Rate (Per 1000 Doses) of Fever Through 4 to 7 Days After Dose 3
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 7 Days After Dose 3
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 3
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of all seizure events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Doses) of All Seizures Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of febrile seizure events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Doses) of Apnea Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 3 Days After Dose 4
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after Dose 4
Incidence Rate (Per 1000 Doses) of Fever Through 4 to 7 Days After Dose 4
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 7 Days After Dose 4
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after Dose 4
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after all doses
Incidence Rate (Per 1000 Doses) of All Seizures Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after all doses
Incidence Rate (Per 1000 Doses) of All Seizures Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of all seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after all doses
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after all doses
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after all doses
Incidence Rate (Per 1000 Doses) of Febrile Seizures Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of febrile seizures events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after all doses
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 3 days after all Doses
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 4 to 7 days after all Doses
Incidence Rate (Per 1000 Doses) of Urticaria and Angioedema Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of urticaria and angioedema events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Urticaria represents an allergic reaction. Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or mucous membranes.
Time frame: 0 to 7 days after all Doses
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 3 days after all Doses
Incidence Rate (Per 1000 Doses) of Apnea Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 4 to 7 days after all Doses
Incidence Rate (Per 1000 Doses) of Apnea Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of apnea events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000. Apnea is the cessation of breathing.
Time frame: 0 to 7 days after all Doses
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 3 Days After All Doses
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-3 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 3 days after all doses
Incidence Rate (Per 1000 Doses) of Fever Through 4 to 7 Days After All Doses
Incidence rate was calculated as the number of fever events experienced during the specified risk window (4-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 4 to 7 days after all doses
Incidence Rate (Per 1000 Doses) of Fever Through 0 to 7 Days After All Doses
Incidence rate was calculated as the number of fever events experienced during the specified risk window (0-7 days post-vaccination) divided by the number of doses, multiply by 1000.
Time frame: 0 to 7 days after all doses